These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35049017)

  • 21. Clinical trials in group 3 pulmonary hypertension.
    Harder EM; Waxman AB
    Curr Opin Pulm Med; 2020 Sep; 26(5):391-396. PubMed ID: 32657833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis.
    Zhang H; Li X; Huang J; Li H; Su Z; Wang J
    Medicine (Baltimore); 2016 Jan; 95(4):e2575. PubMed ID: 26825901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.
    Budev MM; Minai OA; Arroliga AC
    Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostacyclin therapies for the treatment of pulmonary arterial hypertension.
    Gomberg-Maitland M; Olschewski H
    Eur Respir J; 2008 Apr; 31(4):891-901. PubMed ID: 18378784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension.
    Burger CD; Wu B; Classi P; Morland K
    J Manag Care Spec Pharm; 2023 Jan; 29(1):101-108. PubMed ID: 36580122
    [No Abstract]   [Full Text] [Related]  

  • 27. Prostacyclin and its analogues in the treatment of pulmonary hypertension.
    Olschewski H; Rose F; Schermuly R; Ghofrani HA; Enke B; Olschewski A; Seeger W
    Pharmacol Ther; 2004 May; 102(2):139-53. PubMed ID: 15163595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of inhaled nitric oxide with aerosolized prostacyclin or analogues for the postoperative management of pulmonary hypertension: a systematic review and meta-analysis.
    Chen SH; Chen LK; Teng TH; Chou WH
    Ann Med; 2020; 52(3-4):120-130. PubMed ID: 32204626
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostanoids for pulmonary arterial hypertension.
    Galiè N; Manes A; Branzi A
    Am J Respir Med; 2003; 2(2):123-37. PubMed ID: 14720012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery.
    Kuwano K; Hashino A; Noda K; Kosugi K; Kuwabara K
    J Pharmacol Exp Ther; 2008 Sep; 326(3):691-9. PubMed ID: 18552131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of pulmonary hypertension.
    Hoeper MM; McLaughlin VV; Dalaan AM; Satoh T; Galiè N
    Lancet Respir Med; 2016 Apr; 4(4):323-36. PubMed ID: 26975811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension.
    Ewert R; Habedank D; Halank M; Stubbe B; Opitz CF
    Expert Rev Respir Med; 2022 Jan; 16(1):57-66. PubMed ID: 34846985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost-A Multicentre, Retrospective Study.
    Camara RP; Coelho FDN; Cruz-Martins N; Marques-Alves P; Castro G; Baptista R; Ferreira F
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension.
    O'Connell C; Amar D; Boucly A; Savale L; Jaïs X; Chaumais MC; Montani D; Humbert M; Simonneau G; Sitbon O
    Drug Saf; 2016 Apr; 39(4):287-94. PubMed ID: 26748508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.
    Olschewski H; Walmrath D; Schermuly R; Ghofrani A; Grimminger F; Seeger W
    Ann Intern Med; 1996 May; 124(9):820-4. PubMed ID: 8610951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.
    Whittle BJ; Silverstein AM; Mottola DM; Clapp LH
    Biochem Pharmacol; 2012 Jul; 84(1):68-75. PubMed ID: 22480736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical therapy of pulmonary hypertension. The prostacyclins.
    Galié N; Manes A; Branzi A
    Clin Chest Med; 2001 Sep; 22(3):529-37, x. PubMed ID: 11590846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of Pulmonary Arterial Hypertension in the Pediatric Patient.
    Ezekian JE; Hill KD
    Curr Cardiol Rep; 2019 Nov; 21(12):162. PubMed ID: 31781972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhaled iloprost for the control of acute pulmonary hypertension in children: a systematic review.
    Mulligan C; Beghetti M
    Pediatr Crit Care Med; 2012 Jul; 13(4):472-80. PubMed ID: 21926655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension.
    Sarangarm P; Elwood K
    Am J Health Syst Pharm; 2021 Nov; 78(23):2110-2115. PubMed ID: 34100906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.